According to the study, the SMS read, “Influenza may be serious for children with specific medical conditions. The Women’s and Children’s Hospital recommends the influenza vaccine for all medically at-risk children. *NAME* is recommended to receive the influenza vaccine. The vaccine is free and available at GP clinics or at the WCH. Ask at your upcoming WCH appt. If your child has already received the 2021 Flu vaccine, please reply “1.” Reply “STOP” to opt out.”
The primary endpoint of the study was the receipt of at least 1 dose of influenza vaccine by the end of the study period (September 30, 2023), confirmed by the Australian Immunization Register. Secondary endpoints included receipt of at least 1 influenza vaccine dose during the optimal April 1 to June 30 period for those randomly assigned on or before June 15, and days between random assignment and receipt of vaccination.
For the SMS intervention group, influenza vaccination was 38.6% (113 of 293) compared to the control group which was 26.2% (79 of 302) (adjusted odds ratio [aOR], 1.79; 95% CI, 1.27-2.55 [P = .001]). Time to receipt of vaccine was significantly lower in the SMS intervention group compared to control (adjusted hazard ratio 1.67; 95% CI, 1.25-2.22 [P < .001]).
There were 387 participants randomly assigned before June 15, 2021. Among these participants, the probability of vaccination in the optimal April 1 to June 30, 2021 period was higher in the SMS intervention group compared to the control group “(SMS group: 40.0% [76 of 190] vs 25.4% [50 of 197]; aOR, 1.97; 95% CI, 1.28-3.06; P = .002).”
Results from the RCT suggest that SMS nudge reminders for parents of children with SRMCs was superior to clinician nudges alone, in a tertiary care setting, leading to higher vaccine receipt in the optimal seasonal influenza period.
Reference:
Tuckerman J, Harper K, Sullivan TR, et al. Short message service reminder nudge for parents and influenza vaccination uptake in children and adolescents with special risk medical conditions: the Flutext-4U randomized clinical trial. JAMA Pediatr. 2023;177(4):337–344. doi:10.1001/jamapediatrics.2022.6145.